Zoetis

U.S. large-cap biopharma stocks underperformed the broader market for two consecutive years due to political uncertainty and sector rotation. JP Morgan analysts remain positive on key players like Eli Lilly, Bristol-Myers Squibb, Merck & Co., Regeneron Pharmaceuticals, Gilead Sciences, and AbbVie Inc. Animal health stocks, including Zoetis Inc and IDEXX Laboratories, are also projected to rebound in 2025. Specialty pharmaceuticals showed early signs of stabilization in 2024.

Alphabet Inc. (NASDAQ:GOOGL) ranks 4th on a list of AI stocks investors might have missed. Executives from Squarespace, Zoetis, and Varonis discuss AI's impact on website design, animal health, and cybersecurity. Waymo, owned by Alphabet, plans to expand its robotaxi service to Miami in 2025. The article highlights GOOGL's advancements in AI with its Gemini model and TPU chips.

Animal Biotechnology integrates biological sciences and technologies to improve livestock management, disease control, and animal health, addressing global challenges like food security and climate change. The market is set for growth, driven by technological advancements in genomics and rising consumer demand for high-quality animal products. Key players include Bayer AG, Pfizer, Inc., Sanofi, and others, with opportunities for new entrants in precision breeding and vaccines. STATS N DATA's report offers insights into market trends, growth drivers, and regional analysis to 2031.

The U.S. animal health market was valued at USD 12.65 billion in 2024 and is projected to grow at a CAGR of 7.97% from 2025 to 2030, driven by innovations in companion animal pharmaceuticals, rising pet adoption, and increased livestock production. Key diseases in pets include cancer, heartworm, and diabetes, necessitating timely diagnosis and treatment. Pet insurance premiums rose from USD 1.5 billion in 2019 to USD 3.9 billion in 2023, reflecting growing veterinary care costs. Market growth is also supported by advancements in veterinary medicine, early disease detection, and personalized treatments. Major players like Zoetis Inc. and Elanco Animal Health are expanding through product launches and acquisitions to enhance market presence.

AVMA-funded research on reducing veterinarian burnout enters next phase in 2025; practices can participate in training valued at $5,000, with $100 per participant and a chance to win $1,000. Enrollment ongoing through early January.

FDA approves first generic propofol injectable emulsion for dogs, PropofolVet Multidose by Parnell Technologies, bioequivalent to Zoetis' PropoFlo 28, indicated for anesthesia induction and maintenance.

GeneDx appoints Heidi Chen as Chief Legal Officer, effective November 25, 2024, to lead legal, compliance, and policy functions, bringing over 30 years of experience from Zoetis and Pfizer.

The FTC's 2023 revised merger guidelines impact pharmaceutical industries with stricter HHI and market share requirements, emphasizing direct evidence of market dominance and ecosystem competition. The FTC scrutinizes pharmaceutical mergers for market concentration, innovation, and entry barriers, with ongoing investigations into Novo Nordisk/Catalent and AbbVie/Cerevel mergers. The EC investigates Zoetis for potential abuse of dominance post-merger, and the FTC challenges fraudulent patents to prevent market monopolization. Pharmaceutical companies are increasingly merging with biotech firms to offset patent expirations and enhance product portfolios.

The Global Animal Biotechnology Market 2024 report by Coherent Market Insights details market dynamics, value chain, investment hotspots, competitive scenarios, and regional landscapes. Key players include Heska Corporation, Indian Immunologicals Ltd., and HESTER BIOSCIENCES LIMITED. The report offers insights into market segmentation, financial analysis, and strategic decision-making, aiding stakeholders in gaining a competitive edge.

The microfluidic technology market is expected to grow from $3.98 billion in 2024 to $10.81 billion by 2032, driven by advancements in biotechnology, pharmaceuticals, and diagnostics. Key players include Agilent Technologies, Thermo Fisher Scientific, and Danaher, focusing on product development and strategic initiatives. Market segments include diagnostics, drug delivery, and cell culture, with North America leading in market share.